Kemp Dolliver
Stock Analyst at Brookline Capital
(0)
# 5035
Out of 5,319 analysts
24
Total ratings
16.67%
Success rate
-38.86%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
YMAB Y-mAbs Therapeutics | Initiates Coverage On: Buy | 17 | 4.69 | 262.47% | 1 | Dec 5, 2024 | |
EYEN Eyenovia | Downgrades: Hold | n/a | n/a | n/a | 2 | Nov 15, 2024 | |
VRCA Verrica Pharmaceutic... | Downgrades: Hold | n/a | n/a | n/a | 2 | Oct 2, 2024 | |
ONCT Oncternal Therapeuti... | Downgrades: Hold | n/a | n/a | n/a | 3 | Sep 12, 2024 | |
IBIO iBio | Initiates Coverage On: Buy | 4 | 0.89 | 304.49% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 36 | 2.9 | 1141.38% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | n/a | n/a | n/a | 1 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 32 | 1.45 | 2065.52% | 1 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 27 13 | n/a | n/a | 1 | Dec 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | n/a | n/a | n/a | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 100 | 101.32 | -1.3% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 57 | 2.26 | 2422.12% | 2 | Oct 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 5 | n/a | n/a | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Hold | 25 | 2.63 | 850.57% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | n/a | n/a | n/a | 1 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 19 | 6.02 | 211.46% | 1 | Jan 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Buy | 8 | 0.9 | 788.89% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 6 | 1.12 | 404.46% | 1 | Feb 2, 2022 |